Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARM NASDAQ:CNSP NASDAQ:HOTH NASDAQ:MRKR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARMCarisma Therapeutics$0.39-0.8%$0.34$0.14▼$1.27$16.52M1.923.74 million shs474,582 shsCNSPCNS Pharmaceuticals$0.80-10.7%$0.98$0.73▼$62.00$4.89M2.58702,084 shs502,688 shsHOTHHoth Therapeutics$1.25-6.7%$1.15$0.58▼$3.80$17.70M0.673.73 million shs391,829 shsMRKRMarker Therapeutics$1.70-11.5%$1.46$0.95▼$5.95$21.72M1.43342,236 shs1.77 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARMCarisma Therapeutics-0.78%-1.95%-21.92%+104.27%-68.87%CNSPCNS Pharmaceuticals-11.11%-8.55%-3.82%-2.44%-98.55%HOTHHoth Therapeutics-6.72%-13.19%-6.72%+58.71%+32.99%MRKRMarker Therapeutics-11.46%-0.58%+15.65%+47.83%-71.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARMCarisma Therapeutics3.0588 of 5 stars3.25.00.00.03.30.80.6CNSPCNS Pharmaceuticals2.0333 of 5 stars3.34.00.00.01.60.00.6HOTHHoth Therapeutics3.1651 of 5 stars3.65.00.00.03.30.00.6MRKRMarker Therapeutics4.3076 of 5 stars3.85.00.03.92.50.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARMCarisma Therapeutics 2.71Moderate Buy$1.93390.82% UpsideCNSPCNS Pharmaceuticals 2.50Moderate Buy$25.003,025.00% UpsideHOTHHoth Therapeutics 3.25Buy$4.00220.00% UpsideMRKRMarker Therapeutics 3.50Strong Buy$13.17674.51% UpsideCurrent Analyst Ratings BreakdownLatest CNSP, HOTH, CARM, and MRKR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025CARMCarisma TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/26/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.006/12/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.005/22/2025CNSPCNS PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARMCarisma Therapeutics$19.63M0.83N/AN/A($0.67) per share-0.59CNSPCNS PharmaceuticalsN/AN/AN/AN/A$5.37 per shareN/AHOTHHoth TherapeuticsN/AN/AN/AN/A$0.86 per shareN/AMRKRMarker Therapeutics$6.59M2.92N/AN/A$1.73 per share0.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARMCarisma Therapeutics-$60.48M-$1.56N/AN/AN/A-254.28%N/A-137.38%8/6/2025 (Estimated)CNSPCNS Pharmaceuticals-$14.86M-$3,748.50N/A∞N/AN/A-385.41%-193.20%8/13/2025 (Estimated)HOTHHoth Therapeutics-$8.19M-$1.14N/AN/AN/AN/A-109.18%-100.22%8/8/2025 (Estimated)MRKRMarker Therapeutics-$10.73M-$1.33N/AN/AN/A-224.46%-101.87%-83.02%8/13/2025 (Estimated)Latest CNSP, HOTH, CARM, and MRKR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025MRKRMarker Therapeutics-$0.55N/AN/AN/A$0.72 millionN/A8/8/2025N/AHOTHHoth Therapeutics-$0.27N/AN/AN/AN/AN/A5/15/2025Q1 2025CNSPCNS PharmaceuticalsN/A-$1.58N/A-$1.58N/AN/A5/13/2025Q1 2025CARMCarisma Therapeutics-$0.17-$0.22-$0.05-$0.22$2.47 million$3.65 million5/12/2025Q1 2025HOTHHoth Therapeutics-$0.34-$0.27+$0.07-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARMCarisma TherapeuticsN/AN/AN/AN/AN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/AN/AHOTHHoth TherapeuticsN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARMCarisma TherapeuticsN/A1.341.34CNSPCNS PharmaceuticalsN/A4.944.94HOTHHoth TherapeuticsN/A15.0915.08MRKRMarker TherapeuticsN/A6.796.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARMCarisma Therapeutics44.27%CNSPCNS Pharmaceuticals14.02%HOTHHoth Therapeutics7.08%MRKRMarker Therapeutics22.39%Insider OwnershipCompanyInsider OwnershipCARMCarisma Therapeutics6.90%CNSPCNS Pharmaceuticals0.07%HOTHHoth Therapeutics6.92%MRKRMarker Therapeutics14.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARMCarisma Therapeutics2041.79 million38.91 millionNo DataCNSPCNS Pharmaceuticals55.46 million5.46 millionNot OptionableHOTHHoth Therapeutics413.21 million12.30 millionNot OptionableMRKRMarker Therapeutics6011.31 million9.67 millionNot OptionableCNSP, HOTH, CARM, and MRKR HeadlinesRecent News About These CompaniesMarker Therapeutics Insider Trading Activity | NASDAQ:MRKR | BenzingaJuly 18 at 5:59 PM | benzinga.comHere's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn SituationJuly 11, 2025 | finance.yahoo.comMarker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with LymphomaJune 17, 2025 | globenewswire.comMarker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with LymphomaMay 20, 2025 | globenewswire.comMarker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell TherapiesMay 19, 2025 | globenewswire.comArkansas Historic Preservation Program hosts National Historic Marker WeekendApril 17, 2025 | stuttgartdailyleader.comSMarker Therapeutics (MRKR) Receives a Buy from Canaccord GenuityApril 1, 2025 | markets.businessinsider.comMarker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology ConferenceApril 1, 2025 | markets.businessinsider.comMarker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology ConferenceApril 1, 2025 | globenewswire.comMarker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last yearMarch 31, 2025 | markets.businessinsider.comMarker Therapeutics Reports Year-End 2024 Corporate and Financial ResultsMarch 31, 2025 | globenewswire.comMarker Therapeutics stockholder vote clears warrant issuanceMarch 28, 2025 | investing.comMarker Therapeutics initiated with a Buy at CanaccordMarch 5, 2025 | markets.businessinsider.comCanaccord Genuity Initiates Coverage of Marker Therapeutics (MRKR) with Buy RecommendationMarch 5, 2025 | msn.comMarker Therapeutics, Inc. CEO Juan Vera to Present at H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceFebruary 25, 2025 | quiverquant.comQMarker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceFebruary 25, 2025 | globenewswire.comMRKR stock touches 52-week low at $1.61 amid market challengesFebruary 12, 2025 | msn.comBrookline Capital sets $4 target on Marker Therapeutics stockFebruary 11, 2025 | msn.comMarker Therapeutics initiated with a Buy at BrooklineFebruary 11, 2025 | markets.businessinsider.comMRKR stock touches 52-week low at $1.8 amid market challengesJanuary 31, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNSP, HOTH, CARM, and MRKR Company DescriptionsCarisma Therapeutics NASDAQ:CARM$0.39 0.00 (-0.78%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.39 0.00 (-0.82%) As of 07/18/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.CNS Pharmaceuticals NASDAQ:CNSP$0.80 -0.10 (-10.71%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.80 +0.00 (+0.50%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Hoth Therapeutics NASDAQ:HOTH$1.25 -0.09 (-6.72%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.25 +0.00 (+0.40%) As of 07/18/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Marker Therapeutics NASDAQ:MRKR$1.70 -0.22 (-11.46%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.70 0.00 (0.00%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
